bioRxiv Science⌕ Search

Biology subjects

Leahy, K. J.

Publications and source records attributed to Leahy, K. J..

2 recordsLinked to original sources

Explainable Physicochemical Determinants of Protein Ligand Binding via Non-Covalent Interactions

Protein-ligand binding governs enzymatic catalysis, metabolic homeostasis, and therapeutic modulation. Thus, the accurate prediction of these interactions underpins modern rational drug discovery. However, existing deep-learning frameworks largely operate as black-box predictors that fail to resolve the individual residues mediating binding or decode the fundamental non-covalent forces that drive molecular recognition. To address these limitations, we present ExplainBind, an interaction-aware framework that predicts binding likelihood, localizes specific binding residues at single-amino-acid resolution rather than coarse pocket-level regions, and decodes the underlying non-covalent interaction patterns, all zero-shot, without requiring prior three-dimensional structural inputs. To support residue- and interaction-level training and evaluation, we construct InteractBind, a protein-ligand benchmark with residue-atom interaction maps. Simultaneously, benchmarking experiments demonstrate that ExplainBind consistently outperforms state-of-the-art baselines across diverse protein and ligand spaces, maintaining high precision when generalized to entirely novel sequences and chemical scaffolds. When applied to two unseen therapeutic targets, ExplainBind successfully ranks potent angiotensin-converting enzyme (ACE) inhibitors and clarifies differences in their potency via affinity-stratified interaction landscapes. Furthermore, we demonstrate the prospective utility of ExplainBind by discovering novel inhibitors and activators of L-2-hydroxyglutarate dehydrogenase (L2HGDH) through wet-lab validation, with mechanistically distinct interaction profiles providing a clear molecular rationale for their divergent functional outcomes. Collectively, these results establish ExplainBind as a powerful, generalizable tool for mechanistically informed, interpretable drug discovery.

molecular biology↗

Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis

Myofibroblast differentiation, essential for driving extracellular matrix synthesis in pulmonary fibrosis, requires increased glycolysis. While glycolytic cells must export lactate, the contributions of lactate transporters to myofibroblast differentiation are unknown. In this study, we investigated how MCT1 and MCT4, key lactate transporters, influence myofibroblast differentiation and experimental pulmonary fibrosis. Our findings reveal that inhibiting MCT1 or MCT4 reduces TGF{beta}-stimulated pulmonary myofibroblast differentiation in vitro and decreases bleomycin-induced pulmonary fibrosis in vivo. Through comprehensive metabolic analyses, including bioenergetics, stable isotope tracing, metabolomics, and imaging mass spectrometry in both cells and mice, we demonstrate that inhibiting lactate transport enhances oxidative phosphorylation, reduces reactive oxygen species production, and diminishes glucose metabolite incorporation into fibrotic lung regions. Furthermore, we introduce VB253, a novel MCT4 inhibitor, which ameliorates pulmonary fibrosis in both young and aged mice, with comparable efficacy to established antifibrotic therapies. These results underscore the necessity of lactate transport for myofibroblast differentiation, identify MCT1 and MCT4 as promising pharmacologic targets in pulmonary fibrosis, and support further evaluation of lactate transport inhibitors for patients for whom limited therapeutic options currently exist. SUMMARYSmall molecule inhibitors of lactate transporters, including the novel MCT4 inhibitor VB253, reprogram fibroblast metabolism to prevent myofibroblast differentiation and decrease bleomycin-induced pulmonary fibrosis.

cell biology↗